Page last updated: 2024-09-03

y 27632 and alpha-synuclein

y 27632 has been researched along with alpha-synuclein in 1 studies

Compound Research Comparison

Studies (y 27632)	Trials (y 27632)	Recent Studies (post-2010) (y 27632)	Studies (alpha-synuclein)	Trials (alpha-synuclein)	Recent Studies (post-2010) (alpha-synuclein)
1,924	3	891	10,821	29	8,011

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bähr, M; Becker, S; Dambeck, V; Eckermann, K; Fonseca-Ornelas, L; Koch, JC; Lingor, P; Lopes da Fonseca, T; Outeiro, TF; Tatenhorst, L; Tönges, L; Walle, H; Zweckstetter, M	1

Other Studies

1 other study(ies) available for y 27632 and alpha-synuclein

Article	Year
Fasudil attenuates aggregation of α-synuclein in models of Parkinson's disease. Acta neuropathologica communications, 2016, Apr-22, Volume: 4 Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; alpha-Synuclein; Amides; Animals; Brain; Carrier Proteins; Cell Line, Tumor; Disease Models, Animal; Enzyme Inhibitors; Gene Expression Regulation; Humans; Mice; Mice, Transgenic; Mutation; Nerve Tissue Proteins; Parkinson Disease; Protein Aggregates; Protein Kinase Inhibitors; Psychomotor Performance; Pyridines; Recognition, Psychology; Time Factors; Tyrosine 3-Monooxygenase	2016

Article

Year

Fasudil attenuates aggregation of α-synuclein in models of Parkinson's disease.

Acta neuropathologica communications, 2016, Apr-22, Volume: 4

Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; alpha-Synuclein; Amides; Animals; Brain; Carrier Proteins; Cell Line, Tumor; Disease Models, Animal; Enzyme Inhibitors; Gene Expression Regulation; Humans; Mice; Mice, Transgenic; Mutation; Nerve Tissue Proteins; Parkinson Disease; Protein Aggregates; Protein Kinase Inhibitors; Psychomotor Performance; Pyridines; Recognition, Psychology; Time Factors; Tyrosine 3-Monooxygenase

2016